New Research Points Way to a Reverse Aging. But Don’t Expect a Miracle Drug Anytime Soon

“We think the various causes of aging may be addressable with a single treatment to reset the cell,” said Harvard scientist David Sinclair, the paper’s senior author. “So in the future, we could get one treatment — it could be a pill, it could be an injection — to go back 10 years [in cellular life], and then we’ll repeat that process every 10 years.” That kind of miracle drug won’t be developed overnight. The paper’s authors detail experiments with mice that would have to be replicated in humans before Sinclair’s vision could be realized. Scientists would also have to overcome potential safety and regulatory hurdles. But the paper supports what Sinclair, a genetics professor at Harvard’s Blavatnik Institute and codirector of the Paul F. Glenn Center for Biology of Aging Research, calls the “information theory of aging” that identifies the epigenome as the primary culprit in the aging process. […]

Read More… from New Research Points Way to a Reverse Aging. But Don’t Expect a Miracle Drug Anytime Soon

2022 Most Disruptive MBA Startups: Lime Therapeutics, Harvard Business School

The HBS MBA program provided me with so much: a world-class business education; the ability to bounce ideas off professors and other life sciences practitioners in the Harvard community; a world-class student and alumni network full of depth and breadth; and continual inspiration by the people around me. In addition, being in the MBA program qualified me to earn the Harvard Blavatnik Fellowship. This fellowship, now in its ninth cohort, is an incredible one-year program for Harvard MBAs and post-doctoral students seeking to build bold solutions to healthcare and life sciences challenges. It provides a founder’s salary and some company funding, but most importantly, access to a large and diverse network of biotech executives. Intangibly, the fellowship provides the confidence boost required to take chances at an early-stage life sciences startup. […]

Read More… from 2022 Most Disruptive MBA Startups: Lime Therapeutics, Harvard Business School